Immunovant Reports Positive Initial Phase 2 Results for Batoclimab in Graves’ Disease

December 20, 2023

https://www.globenewswire.com/news-release/2023/12/20/2799661/0/en/Immunovant-Reports-Positive-Initial-Phase-2-Results-for-Batoclimab-in-Graves-Disease.html

NEW YORK, Dec. 20, 2023 (GLOBE NEWSWIRE) — Immunovant, Inc. (Nasdaq:IMVT), a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today announced that results from the initial cohort of patients in an ongoing 24-week Phase 2 clinical trial of batoclimab in patients with Graves’ disease meaningfully exceeded 50% response rates.

Read more at globenewswire.com

Related news for (IMVT)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.